Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$37.0M
Filings
168
Firms Hired
4
Active Period
2005–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
2026 · third_quarter · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $450,000 · Firm income: —
Matched citations: H.R. 4752
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: EISAI INC.
Tax reform, including: H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Client expense: $450,000 · Firm income: —
Matched citations: H.R.1
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
2026 · third_quarter · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $450,000 · Firm income: —
Matched citations: H.R. 3747
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $450,000 · Firm income: —
Matched citations: H.R. 6130
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy Benefit Manager (PBM) reform, 340B Drug Discount Program; H.R.9599 Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act)
Client expense: $450,000 · Firm income: —
Matched citations: H.R.9599
Countering Threats and Attacks on Our Judges Act
2026 · third_quarter · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $450,000 · Firm income: —
Matched citations: S. 2379
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Firm: EISAI INC.
Issues related to pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: $450,000 · Firm income: —
Matched citations: S. 2658
General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $450,000 · Firm income: —
Matched citations: S. 3267
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
2026 · second_quarter · Firm: EISAI INC.
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $790,000 · Firm income: —
Matched citations: H.R. 4752
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · second_quarter · Firm: EISAI INC.
Tax reform, including: H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Client expense: $790,000 · Firm income: —
Matched citations: H.R.1
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
2026 · second_quarter · Firm: EISAI INC.
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $790,000 · Firm income: —
Matched citations: H.R. 3747
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $790,000 · Firm income: —
Matched citations: H.R. 6130
Countering Threats and Attacks on Our Judges Act
2026 · second_quarter · Firm: EISAI INC.
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $790,000 · Firm income: —
Matched citations: S. 2379
Medication Affordability and Patent Integrity Act
2026 · second_quarter · Firm: EISAI INC.
Pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.
Client expense: $790,000 · Firm income: —
Matched citations: S. 2658
General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act
Client expense: $790,000 · Firm income: —
Matched citations: S. 3267
Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2023
2026 · first_quarter · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Client expense: $460,000 · Firm income: —
Matched citations: HR 4752
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · first_quarter · Firm: EISAI INC.
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Client expense: $460,000 · Firm income: —
Matched citations: H.R.1
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Client expense: $460,000 · Firm income: —
Matched citations: HR 6130
Countering Threats and Attacks on Our Judges Act
2026 · first_quarter · Firm: EISAI INC.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Client expense: $460,000 · Firm income: —
Matched citations: S 2379
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Client expense: $460,000 · Firm income: —
Matched citations: S 3267
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: $460,000 · Firm income: —
Matched citations: S.891
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.
Client expense: $710,000 · Firm income: —
Matched citations: H.R.1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: EISAI INC.
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Client expense: $710,000 · Firm income: —
Matched citations: H.R.1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: EISAI INC.
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
Client expense: $710,000 · Firm income: —
Matched citations: H.R.1
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.
Client expense: $710,000 · Firm income: —
Matched citations: HR 6130
Source: Senate LDA